Idexx Laboratories Inc. (IDXX) Reaches New 12-Month High at $112.48
Idexx Laboratories Inc. (NASDAQ:IDXX) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $112.48 and last traded at $112.46, with a volume of 179,967 shares traded. The stock had previously closed at $110.15.
A number of research analysts have recently issued reports on IDXX shares. Zacks Investment Research downgraded shares of Idexx Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, July 4th. Canaccord Genuity boosted their price target on shares of Idexx Laboratories from $90.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 20th. Northcoast Research upgraded shares of Idexx Laboratories from a “sell” rating to a “neutral” rating in a research report on Wednesday, August 3rd. Finally, Stifel Nicolaus restated a “buy” rating and issued a $120.00 price target (up previously from $92.00) on shares of Idexx Laboratories in a research report on Wednesday, August 3rd. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Idexx Laboratories presently has an average rating of “Buy” and an average price target of $105.20.
The stock’s 50-day moving average price is $103.34 and its 200-day moving average price is $88.28. The company has a market cap of $10.12 billion and a P/E ratio of 51.25.
Idexx Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported $0.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.12. The company earned $467 million during the quarter, compared to the consensus estimate of $444.83 million. During the same quarter last year, the company posted $0.60 earnings per share. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. Analysts expect that Idexx Laboratories Inc. will post $2.36 earnings per share for the current fiscal year.
In other Idexx Laboratories news, insider Michael J. Phd Williams sold 49,560 shares of the stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $108.94, for a total transaction of $5,399,066.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director William T. End sold 5,000 shares of the stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $108.50, for a total transaction of $542,500.00. Following the transaction, the director now owns 53,564 shares in the company, valued at $5,811,694. The disclosure for this sale can be found here.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.